Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.70 |
| ▸ | MAG | P20916 | 9/20 | 0.67 |
| ▸ | SELP | P16109 | 2/20 | 0.66 |
| ▸ | SELL | P14151 | 1/20 | 0.66 |
| ▸ | SELE | P16581 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390469 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL25658073 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30001490 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL14362211 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL19922285 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL24529621 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL29357459 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL4312517 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL20885234 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL25662685 | 1.00 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12128069-B2 | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-10-29 | — | — | US | claimed |
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | THE BROAD INSTITUTE, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-20240166755-A1 | CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER | UNIV SOUTHERN CALIFORNIA (US) | 2024-05-23 | — | — | US | claimed |
| WO-2024092508-A1 | USE OF MESENCHYMAL STEM CELL | 卡瑞济(北京)生命科技有限公司 | 2024-05-10 | — | — | WO | claimed |
| US-20230312677-A1 | CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | NOVARTIS AG (CH) | 2023-10-05 | — | — | US | claimed |
| US-11535662-B2 | CD28 compositions and methods for chimeric antigen receptor therapy | NOVARTIS AG (CH) | 2022-12-27 | — | — | US | claimed |
| EP-3119423-B1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2022-12-14 | — | — | EP | claimed |
| US-11504338-B2 | GM3 functionalized nanoparticles | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-11-22 | — | — | US | claimed |
| EP-4043485-A1 | CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | Novartis AG (CH) | 2022-08-17 | — | — | EP | claimed |
| WO-2022057941-A1 | IMMUNE EFFECTOR CELL EXPRESSING IL-7R BINDING PROTEIN | 克莱格医学有限公司 | 2022-03-24 | — | — | WO | claimed |
| EP-3325504-B1 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20260139236-A1 | REPROGRAMABLE TNPB POLYPEPTIDES AND USE THEREOF | THE BROAD INST INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12630604-B2 | Methods of making chimeric antigen receptor-expressing cells | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| US-20260130938-A1 | NOVEL RECEPTORS FOR TRANSCRIPTION REGULATION | ARSENAL BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622929-B2 | Genetically engineered hematopoietic stem cells and uses thereof | SYZYGYMED INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-11254743-B2 | Anti-CD33 antibodies and methods of use thereof | ALECTOR LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220047677-A1 | IMMUNE CELL FUNCTION | KITE PHARMA, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3953455-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | Novartis AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-20220041984-A1 | MOBILIZED PERIPHERAL BLOOD AS A SOURCE OF MODIFIED IMMUNE CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2022-02-10 | — | — | US | disclosed |
| WO-2022025220-A1 | PHARMACEUTICAL COMPOSITION INCLUDING CELL EXPRESSING CHIMERIC RECEPTOR | 中外製薬株式会社 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12128069-B2 | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker | PRKCA, PRKCH, PRKCB | SIGLEC7 644/4885MAG 2223/4885SELP 2536/4885 |
| US-20260130938-A1 | NOVEL RECEPTORS FOR TRANSCRIPTION REGULATION | TMIGD3, TMPRSS11D, TM9SF2 | SIGLEC7 365/4885MAG 759/4885SELP 219/4885 |
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | KLRK1, CD47, FCGR3B | SIGLEC7 14/4885MAG 363/4885SELP 296/4885 |
| US-20260139236-A1 | REPROGRAMABLE TNPB POLYPEPTIDES AND USE THEREOF | RBM26, TRRAP, RNASEL | SIGLEC7 3379/4885MAG 2899/4885SELP 3296/4885 |
| US-12630604-B2 | Methods of making chimeric antigen receptor-expressing cells | ICOS, CD40, HAVCR2 | SIGLEC7 121/4885MAG 1635/4885SELP 721/4885 |
| US-20230312677-A1 | CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | ICOS, CD47, CD40 | SIGLEC7 149/4885MAG 606/4885SELP 556/4885 |
| US-12622929-B2 | Genetically engineered hematopoietic stem cells and uses thereof | CD2, FCGR3B, SIGLEC9 | SIGLEC7 8/4885MAG 883/4885SELP 126/4885 |
| US-11535662-B2 | CD28 compositions and methods for chimeric antigen receptor therapy | ICOS, CD47, CD40 | SIGLEC7 149/4885MAG 606/4885SELP 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.